Transition raises $17M in new capital

In a private placement, Transition Therapeutics (TTHI +1.4%) raises $17M via the sale of 3,195,487 units at $5.32. Each unit consists of one share of common stock and 0.61 of a warrant to purchase one share of common at $7.10 for a term of two years. If all warrants are exercised, the total capital raised will be $30.8M.

Proceeds will fund the completion of the Phase 2 clinical trial of ELND005 for Alzheimer's disease-associated agitation and aggression and the Phase 2 trial of TT-401 as a treatment for Type 2 diabetes.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs